

STRUEWING BIBLIOGRAPHY

February 2003

Book Chapters\Invited Reviews

1. Jacobs IJ, Shepherd JH, Oram DH, et al. "The penetrance of *BRCA1/2* mutations" in Ovarian Cancer. Oxford: Oxford University Press, 2002:427.
2. Struewing JP. *BRCA1* in special populations. *Breast Dis* 1998; 10:71-5.

Journal Articles

1. Ash SR, Struewing JP. Clinical trials of column disc peritoneal catheter (Lifecath, TM). *Peritoneal Dialysis Bull* 1983;3:77-80.
2. Epstein RS, Struewing JP, Sharkness CM, Lefkowitz A, Cadigan DA, Flynn JPG, Kessler II. Secular changes in case mix of SCI patients at Montebello. *Maryland Med J* 1988;37:291-6.
3. Epstein RS, Lefkowitz A, Sharkness CM, Struewing JP, Cadigan DA, Kessler II, Flynn JPG. Predictors of rehabilitation outcome among patients with SCI. *Maryland Med J* 1989;38:489-92.
4. Abdel-Wahab MF, Esmat G, Narooz SI, Yosery A, Struewing JP, Strickland GT. Sonographic studies of schoolchildren in a village endemic for *Schistosoma mansoni*. *Trans Royal Soc Trop Med Hygiene* 1990;84:69-73.
5. Struewing JP, Gray GC. An epidemic of respiratory complaints exacerbated by mass psychogenic illness in a military recruit population. *Am J Epidemiol* 1990;132:1120-9.
6. Gray GC, Escamilla J, Hyams KC, Struewing JP, Kaplan EL, Tupponce AK. Hyperendemic *Streptococcus pyogenes* infection despite prophylaxis with penicillin G benzathine. *N Engl J Med* 1991;325:92-7.
7. Gray GC, Struewing JP, Clever GC, Kulhenkamp JF. Worst California measles epidemic in twenty-five years. *Navy Med* 1991;82(4):23-5.
8. Struewing JP, Pape DM, Snow DA. Improving colorectal cancer screening in a medical residents' primary care clinic. *Am J Prev Med* 1991;7:75-81.
9. Fujikawa J, Struewing JP, Hyams KC, Kaplan EL, Tupponce AK, Gray GC. Oral erythromycin prophylaxis against *Streptococcus pyogenes* infection in penicillin-allergic military recruits: a randomized clinical trial. *J Infect Dis* 1992;166:162-5.
10. Bassily S, Strickland GT, Abdel-Wahab MF, Esmat GE, Narooz S, el-Masry NA, Constantine NT, Struewing JP. Efficacy of hepatitis B vaccination in primary school children from a village endemic for *Schistosoma mansoni*. *J Infect Dis* 1992;166:265-8.
11. Hyams KC, Struewing JP, Gray GC. Seroprevalence of hepatitis A, B, and C in a United States military recruit population. *Military Med* 1992;157:579-82.
12. Trump, DH, Hyams KC, Cross ER, Struewing JP. Tuberculosis infection among young adults entering the US Navy in 1990. *Arch Intern Med* 1993; 153:211-6.
13. Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. *Cancer* 1993;71:566-72.
14. Gray GC, Struewing JP, Escamilla J, Hyams KC, Escamilla J, Tupponce AK, Kaplan EL. Interpreting a single anti-streptolysin O test: a comparison of the "upper limit of normal" and likelihood ratio methods. *J Clin Epidemiol* 1993;46:1181-5.

15. Musher DM, Groover JE, Rowland JM, Watson DA, Struewing JP, Baughn RE, Mufson MA. Antibody to capsular polysaccharides of *Streptococcus pneumoniae*: prevalence, persistence, and response to revaccination. *Clin Infect Dis* 1993;17:66-73.
16. Struewing JP, Hyams KC, Tueller JE, Gray GC. The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits. *Am J Public Health* 1993;83:1717-20.
17. Smith SA, DiCioccio RA, Struewing JP, Easton DF, Gallion HH, Mazoyer S, Johansson B, Steichen-Gersdorf E, Stratton M, Ford D, Marshall G, Piver MS, Ponder BA. Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of ≤ 1 cM. *Genes, Chromosomes & Cancer* 1994;10:71-6.
18. Hussussian CJ*, Struewing JP*, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr., Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. *Nature Genetics* 1994;8:15-21. (* contributed equally to work)
19. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, Ponder BAJ, Weber BL, Garber JE, Birch JM, Cornelis RS, Kelsell DP, Spurr NK, Smyth E, Haites N, Sobol H, Bignon YJ, Chang-Claude J, Hamman U, Lindblom A, Borg A, Piver MS, Gallion HH, Struewing JP, Whittemore A, Tonin P, Goldgar DE, Easton DF, and the Breast Cancer Linkage Consortium. An evaluation of genetic heterogeneity in 145 Breast-Ovarian Cancer Families. *Am J Hum Genet* 1995;56:254-64.
20. Brody LC, Abel KJ, Castilla LH, Couch FJ, McKinley DR, Yin G, Ho PP, Merajver S, Chandrasekharappa SC, Xu J, Cole JL, Struewing JP, Valdes JM, Collins FS, Weber BL. Construction of transcription map surrounding the *BRCA1* locus of human chromosome 17. *Genomics* 1995;25:238-47.
21. Struewing JP, Lerman C, Kase RG, Giambarresi TR, Tucker MA. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. *Cancer Epidemiol Biomarkers Prev* 1995;4:169-73.
22. Struewing JP, Watson P, Easton DF, Ponder BAJ, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. *Monogr Natl Cancer Inst* 1995;17:33-5.
23. Struewing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith SA, Collins FS, Tucker MA. Detection of eight *BRCA1* mutations in ten breast/ovarian cancer families, including one family with male breast cancer. *Am J Hum Genet* 1995;57:1-7.
24. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC. The carrier frequency of the *BRCA1* 185delAG mutation is approximately 1% in Ashkenazi Jewish individuals. *Nature Genet* 1995;11:198-200.
25. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, Tucker MA. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16(INK4) mutations. *New Engl J Med* 1995;333:970-4.
26. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offitt K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop R, Kelsel D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet S, Easton D, Kinc MC, Goldgar DE. Haplotype and phenotype analysis of six recurrent *BRCA1* mutations in 61 families: results of an international study. *Am J Hum Genet* 1996;58:271-80.
27. Struewing JP, Tarone RE, Brody LC, Li FP, Boice JD, Jr. *BRCA1* mutations in young women with breast cancer. *Lancet* 1996; 347:1493.

28. Smith KL, Wilson M, Hightower AW, Kelley PW, Struewing JP, Juranek DD, McAuley JB. Prevalence of *Toxoplasma gondii* antibodies in U.S. military recruits in 1989: comparison with data published in 1965. *Clin Infect Dis* 1996; 23:1182-3.
29. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. *Nat Med* 1996; 2:1179-83.
30. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. *Nat Genet* 1996; 14:188-90.
31. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of *BRCA1* and *BRCA2* among Ashkenazi Jews. *New Engl J Med* 1997; 336:1401-8.
32. Abbaszadegan MR, Struewing JP, Brown KM, Snider JV, Goodsaid F, Gore-Langton R, Hughes MR. Automated detection of prevalent mutations in BRCA1 and BRCA2 genes, using a fluorogenic PCR allelic discrimination assay. *Genetic Testing* 1997; 1:171-180.
33. Emmert-Buck MR, Weiss RA, DiFranco EM, Aznavoorian S, Linehan WM, Vocke C, Chuaqui F, Merino MJ, Liotta LA, Zhuang Z, Struewing JP. Allelic loss on chromosome 8p in BRCA1 mutation positive breast/ovarian cancers. *Breast J* 1998;4:9-12.
34. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* 1998; 62:676-89.
35. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BAJ, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JGM, Devilee P, Cornelisse CJ, Lasset C, Lenoir G, Barkardottir RB, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Stratton MR, Easton DF. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. *J Natl Cancer Inst* 1998; 90:1138-1145.
36. Woodage T, King SM, Wacholder S, Hartge P, Struewing JP, McAdams M, Laken SJ, Tucker MA, Brody LC. The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. *Nat Genet* 1998; 20:62-5.
37. Wacholder S, Hartge P, Struewing JP, Pee D, McAdams M, Brody L, Tucker M. The kin-cohort study for estimating penetrance. *Am J of Epidemiol* 1998; 148:623-630.
38. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. *Lancet* 1998; 352:1337-1339.
39. Lee JS, Wacholder S, Struewing JP, McAdams M, Pee D, Brody LC, Tucker MA, Hartge P. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 1999; 91:259-63.
40. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. *Am J Hum Genet* 1999; 64:963-970.

41. Sherman ME, Lee JS, Burks RT, Struewing JP, Kurman RJ, Hartge P. Histopathologic features of ovaries at increased risk for carcinoma: a case-control analysis. *Int J Gynecol Pathol* 1999; 18:151-7.
42. Kaufman DJ, Struewing J. Re: Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. *J Natl Cancer Inst* 1999; 91:1250-1251.
43. Struewing JP, Coriaty ZM, Ron E, Livoff A, Konichezky M, Cohen P, Resnick MB, Lifzchiz-Mercerl B, Lew S, Iscovich J. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. *Am J Hum Genet* 1999;65:1800-1802.
44. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BAJ, Futreal PA, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Bishop DT, Klijn JGM, Devilee P, Cornelisse CJ, Lasset C, Lenoir G, Barkardottir RB, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Easton DF, Stratton MR. The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. *Clin Cancer Res* 2000; 6:782-789.
45. Biesecker BB, Ishibe N, Hadley DW, Giambarresi TR, Kase RG, Lerman C, Struewing JP. Psychosocial factors predicting *BRCA1/BRCA2* testing decisions in members of hereditary breast and ovarian cancer families. *Am J Med Genet* 2000;93:257-63.
46. Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL, Tucker MA, Bianchi-Scarra G, Bressac-De Paillerets B, Goldstein AM. A single genetic origin for the G101W *CDKN2A* mutation in 20 melanoma-prone families. *Am J Hum Genet* 2000; 67:311-9.
47. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with *CDKN2A* and *CDK4* mutations. *J Natl Cancer Inst* 2000; 92:1006-10.
48. Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, Beck D, Beller U, Ben-Baruch G, Piura B, Friedman E, Struewing JP, Modan B. Patients with double primary tumors in the breast and ovary - Clinical characteristics and BRCA1-2 mutations status. *Gynecologic Oncol* 2000; 79:74-8.
49. Goldstein AM, Liu L, Shennan MG, Hogg D, Tucker MA, Struewing JP. A common founder for the V126D *CDKN2A* mutation in seven North American melanoma-prone families. *Br J Cancer* 2001; 85:527-30.
50. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baruch G, Fishman A, Menczer J, Ebbers SM, Tucker MA, Wacholder S, Struewing JP, Friedman E, Piura B. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a *BRCA1* or *BRCA2* mutation. *N Engl J Med* 2001; 345:235-40.
51. Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP. A single nucleotide polymorphism in the 5' untranslated region of *RAD51* and risk of cancer among *BRCA1/2* mutation carriers. *Cancer Epidemiol Biomarkers Prev* 2001; 10:955-60.
52. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, Ben-Baruch G, Fishman A, Levavi H, Lubin F, Menczer J, Piura B, Struewing JP, Modan B. Effect of *BRCA* mutations on the length of survival in epithelial ovarian tumors. *J Clin Oncol* 2002; 20:463-6.
53. Pfeiffer RM, Rutter JL, Gail MH, Struewing J, Gastwirth JL. Efficiency of DNA pooling to estimate joint allele frequencies and measure linkage disequilibrium. *Genet Epidemiol* 2002; 22:94-102.

54. Hartge P, Chatterjee N, Wacholder S, Brody LC, Tucker MA, Struewing JP. Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: Effects of reproductive history. *Epidemiology* 2002;13:255-61.
55. Tucker MA, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford JT, Chiazze EA, Zametkin DP, Fontaine LS, Clark WH, Jr. A natural history of melanomas and dysplastic nevi. *Cancer* 2002; 94:3192-209.
56. Zhang J, Rowe WL, Struewing JP, Buetow KH. HapScope: a software system for automated and visual analysis of functionally annotated haplotypes. *Nucleic Acids Res* 2002; 30:5213-21.
57. Menczer J, Chetrit A, Barda G, Lubin F, Fishler Y, Altaras M, Levavi H, Struewing JP, Sadetzki S, Modan B. Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women. *Gynecol Oncol* 2003; 88:58-61.